News

Danish pharmaceutical giant Novo Nordisk and U.S. biotech Septerna agreed to collaborate on the development of pills to treat obesity, type 2 diabetes and other metabolic conditions. Under the ...
COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio ...
Danish drug maker Novo Nordisk (NVO) on Tuesday announced an exclusive global collaboration and license agreement with U.S.-based Septerna, Inc. (SEPN) to discover, develop, and commercialise oral ...
Novo Nordisk A/S is partnering with U.S. biotech Septerna Inc. on the development of oral pills for obesity in a deal potentially worth up to $2.2 billion. The two companies will start with four ...